PLENVU (NER 1006) is filed at FDA to provide complete bowel cleansing. Norgine + Salix
Norgine B.V. announced that it has received acceptance from the FDA for the New Drug Application (NDA) for PLENVU (NER 1006). PLENVU is a novel, low-volume (1L) polyethylene glycol based bowel preparation that has been developed to provide complete bowel cleansing, with an additional focus on the ascending colon. In August 2016, Norgine out-licensed PLENVU to Salix in the US and Canada.
PLENVU� (NER1006) is a novel, low volume (1L) polyethylene glycol based bowel preparation that has been developed to provide whole bowel cleansing, with an additional focus on the ascending colon. This low-volume solution is developed not only to support improved patient acceptability and compliance but also to contribute to effectiveness of colonoscopy procedures at detecting colon cancer and for optimised bowel surveillance, through effective bowel cleansing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins